Neuralstem, Inc. (CUR) Reaches $4.15 After 3.00% Down Move, Bank Of Nova Scotia Trust Company Has Upped By $20.61 Million Its Bank N S Halifax (BNS) Stake

May 26, 2017 - By Ellis Scott

The stock of Neuralstem, Inc. (NASDAQ:CUR) is a huge mover today! The stock decreased 5.68% or $0.25 on May 26, reaching $4.15. About 53,383 shares traded. Neuralstem, Inc. (NASDAQ:CUR) has risen 3.35% since May 26, 2016 and is uptrending. It has underperformed by 13.35% the S&P500.The move comes after 9 months negative chart setup for the $49.05M company. It was reported on May, 26 by Barchart.com. We have $4.03 PT which if reached, will make NASDAQ:CUR worth $1.47M less.

Bank Of Nova Scotia Trust Company increased Bank N S Halifax (BNS) stake by 51.15% reported in 2016Q4 SEC filing. Bank Of Nova Scotia Trust Company acquired 374,786 shares as Bank N S Halifax (BNS)’s stock declined 10.69%. The Bank Of Nova Scotia Trust Company holds 1.11M shares with $61.67M value, up from 732,781 last quarter. Bank N S Halifax now has $67.48 billion valuation. The stock increased 0.43% or $0.24 on May 26, reaching $56.4. About 513,635 shares traded. Bank of Nova Scotia (NYSE:BNS) has risen 16.52% since May 26, 2016 and is uptrending. It has underperformed by 0.18% the S&P500.

Bank Of Nova Scotia Trust Company decreased Weyerhaeuser Co (NYSE:WY) stake by 28,095 shares to 10,690 valued at $322,000 in 2016Q4. It also reduced Deere & Co (NYSE:DE) stake by 13,705 shares and now owns 2,400 shares. Unilever N V (NYSE:UN) was reduced too.

Among 8 analysts covering The Bank Of Nova Scotia (NYSE:BNS), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. The Bank Of Nova Scotia had 15 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Friday, August 28. The rating was downgraded by Macquarie Research to “Neutral” on Thursday, June 9. On Wednesday, September 21 the stock rating was initiated by Dundee Securities with “Buy”. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, December 2 report. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, August 31 report. The stock of Bank of Nova Scotia (NYSE:BNS) has “Overweight” rating given on Tuesday, May 23 by Barclays Capital. The stock of Bank of Nova Scotia (NYSE:BNS) earned “Outperform” rating by RBC Capital Markets on Monday, August 31.

Investors sentiment decreased to 0.3 in Q4 2016. Its down 0.37, from 0.67 in 2016Q3. It worsened, as 16 investors sold Neuralstem, Inc. shares while 11 reduced holdings. 2 funds opened positions while 6 raised stakes. 6.88 million shares or 44.05% less from 12.30 million shares in 2016Q3 were reported. National Bank Of America De holds 8,400 shares. Pnc Fin Grp owns 16,000 shares or 0% of their US portfolio. Kcg reported 106,830 shares. Blackrock Advisors Limited Liability Com invested in 0% or 17,361 shares. Moreover, Natl Asset Mngmt Inc has 0.01% invested in Neuralstem, Inc. (NASDAQ:CUR). Moreover, Fifth Third Natl Bank has 0% invested in Neuralstem, Inc. (NASDAQ:CUR) for 120,000 shares. California Public Employees Retirement has invested 0% in Neuralstem, Inc. (NASDAQ:CUR). Blackrock Institutional Company Na stated it has 0% in Neuralstem, Inc. (NASDAQ:CUR). One Trading Limited Partnership stated it has 0% of its portfolio in Neuralstem, Inc. (NASDAQ:CUR). Wells Fargo And Mn has 0% invested in Neuralstem, Inc. (NASDAQ:CUR). The Massachusetts-based Commonwealth Equity Service has invested 0% in Neuralstem, Inc. (NASDAQ:CUR). Goldman Sachs Group Inc owns 10,440 shares. Davenport Ltd Liability reported 24,000 shares. Northern Tru Corp has invested 0% in Neuralstem, Inc. (NASDAQ:CUR). Blackrock Fund, California-based fund reported 24,841 shares.

Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $49.05 million. The Firm is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. It currently has negative earnings. The Firm has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Since January 25, 2017, it had 4 insider purchases, and 0 insider sales for $80,004 activity. Another trade for 2,841 shares valued at $10,000 was bought by Daly Richard J. The insider LLOYD JONES JONATHAN BRIAN bought $30,003.